Chinook Therapeutics CVR
13F holders, Q2 2025 (June 30)4holders −1
0new positions
1sold out
$0.01avg. 13F price*
At the end of Q2 2025, 4 institutions reported holding Chinook Therapeutics CVR in their 13F filings, down 1 from Q1 2025. 0 opened new positions and 1 sold out. The largest holders were Propel Bio Management, LLC ($3K), Rhumbline Advisers ($0) and Sterling Capital Management LLC ($0).
- Company
- Chinook Therapeutics CVR
- CUSIP
- 169CVR016
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $120K |
All 13F filers, Q1 2025 → Q2 2025: 307,846 shares sold, net −307,846 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Propel Bio Management, LLC | 0.00% | No change | 79,357 | $3K |
| Rhumbline Advisers | 0.00% | Reduce -0.0% | 87,704 | $0 |
| Sterling Capital Management LLC | 0.00% | Reduce -4.5% | 1,006 | $0 |
| ORG Partners LLC | 0.00% | No change | 30 | $0 |
"% of holder's portfolio" is CHINOOK THERAPEUTICS CVR's weight in each manager's 13F, not the share of Chinook Therapeutics CVR the manager owns.